You Position: Home > Paper
Cardiac resynchronization therapy and B-type natriuretic peptide in heart failure
( views:90, downloads:4 )
- Author:
- No author available
- Journal Title:
- CHINESE MEDICAL JOURNAL
- Issue:
- 6
- DOI:
- 10.3760/cma.j.issn.0366-6999.2009.06.002
- Key Word:
- No keyword available
Abstract： @@ Cardiac resynchronization therapy (CRT) improves left ventricular function, symptom status, quality of life and reduces hospitalization and mortality in patients with New York Heart Association (NYHA) Class Ⅲ or IV heart failure and intraventricular conduction delay despite optimal medical management.1 B-type natriuretic peptide (BNP) and its amino terminal cleavage equivalent (NT-pro BNP) levels correlate with the severity of heart failure and predict prognosis of heart failure patients.2
- [1]Shankar A,Fruhwald F,Tavazzi L,etc.Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.[J].2008,52(6).
- [2]Dai D,Hernandez AF,Yancy CW,etc.Use of cardiac resynchronization therapy in patients hospitalized with heart failure.[J].2008,118(9).
- [3]Ordonez-Llanos J,Fabregat J,Planas F,etc.Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure.[J].2007,120(3).
- [4]Braunwald E.Biomarkers in heart failure.[J].2008,358(20).
- [5]Dryden DM,Vandermeer B,Hooton N,etc.Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review.[J].2007,297(22).
- [6]William T, Abraham,Westby G, Fisher,Andrew L, Smith,etc.Cardiac resynchronization in chronic heart failure.[J].2002,346(24).